Ajuts a la recerca

Alzheimer’s Drug Discovery Foundation (ADDF)

Organisme

The Alzheimer’s Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer’s disease (AD), related dementias and cognitive aging.

Objecte

The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundatio

Descripció

FUNDING MECHANISMS

•  Academic Drug Discovery and Development Program seeks to create and support innovative translational programs in academic medical centers and universities.
•  Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a program-related investment.
•  Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.
•  Conference Grants support innovative scientific conferences that stimulate discussion around novel targets.

The ADDF provides typically supports one year of research at a time, with potential for future follow-on funding. Funding averages $150,000 per year and must be justified based on the scientific work plan. In some cases, multi-year proposals can be considered. Inquiries with the ADDF staff are encouraged to determine
the Foundation’s interest prior to application.

All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. The
ADDF will attempt to make a determination of interest within 90 days of receipt of the application. Full application guidelines and further information can be found on our website (www.alzdiscovery.org ).
 

Termini oficial

2013 QUARTERLY DEADLINES*

• January 22
• March 5
• June 5
• September 5
• December 5

*All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form.

Termini IISPV

Cal comunicar abans del 28 de desembre de 2012 que es vol participar a la convocatòria, enviant un e-mail a convocatories@iispv.cat . Termini: 14 de gener de 2013

Pujar